Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diethylcarbamazine + albendazole
- Development stage
- Unknown
- Lead developer
- World Health Organization
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A two-drug combination used primarily for the treatment of lymphatic filariasis. Diethylcarbamazine (DEC) acts as a microfilaricidal agent targeting the larval stage of the parasite, while albendazole is a broad-spectrum antihelmintic that disrupts the parasite's metabolism and microtubules. This combination is recommended by the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis for mass drug administration in endemic areas.
- Other names
- DEC + albendazole
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on diethylcarbamazine + albendazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diethylcarbamazine + albendazole.